CanSino Biologics on AstraZeneca Deal, Earnings

The transcript covers a company's financial status, highlighting R&D spending and a one-time write-off related to COVID-19 vaccines. It discusses a collaboration with AstraZeneca to bring mRNA vaccine technology to China. The company is monitoring a new COVID-19 strain and has a candidate vaccine in the pipeline. The impact of a corruption crackdown in China's healthcare sector is addressed, emphasizing ethical practices. The company's vaccine pipeline includes innovative candidates like a polio VLP vaccine, with several products in late-stage trials.

What is the company's approach to maintaining compliance with regulations in light of the corruption crackdown?

What are the expected outcomes of the company's new vaccines in terms of market share?

What innovative vaccines is the company most excited about in its pipeline?